Literature DB >> 25273081

Progress toward curing HIV infections with hematopoietic stem cell transplantation.

Stephen T Smiley1, Anjali Singh1, Sarah W Read1, Opendra K Sharma1, Diana Finzi1, Clifford Lane2, Jeffrey S Rice3.   

Abstract

Combination antiretroviral therapy can suppress human immunodeficiency virus (HIV) infection but cannot completely eradicate the virus. A major obstacle in the quest for a cure is the difficulty in targeting and measuring latently infected cells. To date, a single person seems to have been cured of HIV. Hematopoietic stem cell transplantation (HSCT) preceded this cancer patient's long-term sustained HIV remission, but researchers have been unable to replicate this cure, and the mechanisms that led to HIV remission remain to be established. In February 2014, the National Institute of Allergy and Infectious Diseases sponsored a workshop that provided a venue for in-depth discussion of whether HSCT could be exploited to cure HIV in cancer patients requiring such procedures. Participants also discussed how HSCT might be applied to a broader community of HIV-infected persons in whom the risks of HSCT currently outweigh the likelihood and benefits of HIV cure. Published by Oxford University Press on behalf of the Infectious Diseases Society of America 2014. This work is written by (a) US Government employee(s) and is in the public domain in the US.

Entities:  

Keywords:  HIV; latency; reservoirs; transplantation

Mesh:

Year:  2014        PMID: 25273081      PMCID: PMC4296106          DOI: 10.1093/cid/ciu766

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  40 in total

1.  Persistent HIV-1 replication is associated with lower antiretroviral drug concentrations in lymphatic tissues.

Authors:  Courtney V Fletcher; Kathryn Staskus; Stephen W Wietgrefe; Meghan Rothenberger; Cavan Reilly; Jeffrey G Chipman; Greg J Beilman; Alexander Khoruts; Ann Thorkelson; Thomas E Schmidt; Jodi Anderson; Katherine Perkey; Mario Stevenson; Alan S Perelson; Daniel C Douek; Ashley T Haase; Timothy W Schacker
Journal:  Proc Natl Acad Sci U S A       Date:  2014-01-27       Impact factor: 11.205

Review 2.  The end of AIDS: HIV infection as a chronic disease.

Authors:  Steven G Deeks; Sharon R Lewin; Diane V Havlir
Journal:  Lancet       Date:  2013-10-23       Impact factor: 79.321

3.  Vorinostat plus tacrolimus and mycophenolate to prevent graft-versus-host disease after related-donor reduced-intensity conditioning allogeneic haemopoietic stem-cell transplantation: a phase 1/2 trial.

Authors:  Sung Won Choi; Thomas Braun; Lawrence Chang; James L M Ferrara; Attaphol Pawarode; John M Magenau; Guoqing Hou; Jan H Beumer; John E Levine; Steve Goldstein; Daniel R Couriel; Keith Stockerl-Goldstein; Oleg I Krijanovski; Carrie Kitko; Gregory A Yanik; Michael H Lehmann; Isao Tawara; Yaping Sun; Sophie Paczesny; Markus Y Mapara; Charles A Dinarello; John F DiPersio; Pavan Reddy
Journal:  Lancet Oncol       Date:  2013-11-30       Impact factor: 41.316

Review 4.  The major histocompatibility complex: a model for understanding graft-versus-host disease.

Authors:  Effie W Petersdorf
Journal:  Blood       Date:  2013-07-22       Impact factor: 22.113

5.  Gene editing of CCR5 in autologous CD4 T cells of persons infected with HIV.

Authors:  Pablo Tebas; David Stein; Winson W Tang; Ian Frank; Shelley Q Wang; Gary Lee; S Kaye Spratt; Richard T Surosky; Martin A Giedlin; Geoff Nichol; Michael C Holmes; Philip D Gregory; Dale G Ando; Michael Kalos; Ronald G Collman; Gwendolyn Binder-Scholl; Gabriela Plesa; Wei-Ting Hwang; Bruce L Levine; Carl H June
Journal:  N Engl J Med       Date:  2014-03-06       Impact factor: 91.245

Review 6.  Genetically modified hematopoietic stem cell transplantation for HIV-1-infected patients: can we achieve a cure?

Authors:  Patrick Younan; John Kowalski; Hans-Peter Kiem
Journal:  Mol Ther       Date:  2013-11-13       Impact factor: 11.454

7.  HIV protective KIR3DL1/S1-HLA-B genotypes influence NK cell-mediated inhibition of HIV replication in autologous CD4 targets.

Authors:  Rujun Song; Irene Lisovsky; Bertrand Lebouché; Jean-Pierre Routy; Julie Bruneau; Nicole F Bernard
Journal:  PLoS Pathog       Date:  2014-01-16       Impact factor: 6.823

8.  Replication-competent noninduced proviruses in the latent reservoir increase barrier to HIV-1 cure.

Authors:  Ya-Chi Ho; Liang Shan; Nina N Hosmane; Jeffrey Wang; Sarah B Laskey; Daniel I S Rosenbloom; Jun Lai; Joel N Blankson; Janet D Siliciano; Robert F Siliciano
Journal:  Cell       Date:  2013-10-24       Impact factor: 41.582

9.  Challenges in detecting HIV persistence during potentially curative interventions: a study of the Berlin patient.

Authors:  Steven A Yukl; Eli Boritz; Michael Busch; Christopher Bentsen; Tae-Wook Chun; Daniel Douek; Evelyn Eisele; Ashley Haase; Ya-Chi Ho; Gero Hütter; J Shawn Justement; Sheila Keating; Tzong-Hae Lee; Peilin Li; Danielle Murray; Sarah Palmer; Christopher Pilcher; Satish Pillai; Richard W Price; Meghan Rothenberger; Timothy Schacker; Janet Siliciano; Robert Siliciano; Elizabeth Sinclair; Matt Strain; Joseph Wong; Douglas Richman; Steven G Deeks
Journal:  PLoS Pathog       Date:  2013-05-09       Impact factor: 6.823

Review 10.  The time is now: moving toward virus-specific T cells after allogeneic hematopoietic stem cell transplantation as the standard of care.

Authors:  Francesco Saglio; Patrick J Hanley; Catherine M Bollard
Journal:  Cytotherapy       Date:  2014-02       Impact factor: 5.414

View more
  5 in total

1.  Functionally Active HIV-Specific T Cells that Target Gag and Nef Can Be Expanded from Virus-Naïve Donors and Target a Range of Viral Epitopes: Implications for a Cure Strategy after Allogeneic Hematopoietic Stem Cell Transplantation.

Authors:  Shabnum Patel; Sharon Lam; Conrad Russell Cruz; Kaylor Wright; Christina Cochran; Richard F Ambinder; Catherine M Bollard
Journal:  Biol Blood Marrow Transplant       Date:  2015-12-22       Impact factor: 5.742

2.  Allogeneic MHC-matched T-cell receptor α/β-depleted bone marrow transplants in SHIV-infected, ART-suppressed Mauritian cynomolgus macaques.

Authors:  Jason T Weinfurter; Saritha S D'Souza; Lea M Matschke; Sarah Bennett; Laurel E Kelnhofer-Millevolte; Kran Suknuntha; Akhilesh Kumar; Jennifer Coonen; Christian M Capitini; Peiman Hematti; Thaddeus G Golos; Igor I Slukvin; Matthew R Reynolds
Journal:  Sci Rep       Date:  2022-07-19       Impact factor: 4.996

3.  Implementing Generalized Additive Models to Estimate the Expected Value of Sample Information in a Microsimulation Model: Results of Three Case Studies.

Authors:  Dustin J Rabideau; Pamela P Pei; Rochelle P Walensky; Amy Zheng; Robert A Parker
Journal:  Med Decis Making       Date:  2017-11-09       Impact factor: 2.583

4.  Setting Performance Standards for a Cost-Effective Human Immunodeficiency Virus Cure Strategy in South Africa.

Authors:  A David Paltiel; Amy Zheng; Milton C Weinstein; Melanie R Gaynes; Robin Wood; Kenneth A Freedberg; Paul E Sax; Rochelle P Walensky
Journal:  Open Forum Infect Dis       Date:  2017-04-22       Impact factor: 4.423

5.  Highlights from the 24th Conference on Retroviruses and Opportunistic Infections: 13-16 February 2017, Seattle, Washington, USA.

Authors:  Trevor A Crowell; Hermione Lyall; Eva Malatinkova; Sanjay Bhagani; Denise Hsu; Donn J Colby; Christina Polyak; Christina Psomas; Andrew Hill; Esther N Gathogo; Wim Trypsteen; Linos Vandekerckhove; Sabine Kinloch
Journal:  J Virus Erad       Date:  2017-04-01
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.